Epizyme Inc (NASDAQ: EPZM) has priced its underwritten public offering of 56.7 million shares at .50 per share for gross proceeds of million.
-
The offer price represents a discount of almost 21% from the last close price of $1.90 on Wednesday.
-
Underwriters have an option to purchase up to an additional 8.5 million shares.
-
Epizyme will use the proceeds to fund the global development & commercialization of tazemetostat, Phase 1/1b trial of EZM0414, the discovery & identification of additional product candidates, and fund initiatives to accelerate commercial adoption of TAZVERIK.
-
Earlier this month, the Company posted preliminary Tazverik (tazemetostat) sales of .2 million - 11.7 million in Q4 FY21 and $30.6 million - 31.1 million in FY21.
-
The offering is expected to close by January 31.
-
Price Action: EPZM shares are down 30.5% at $1.32 during the premarket session on the last check Thursday.
See more from Benzinga
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.